The data is now a year old, but it has not been absorbed. In June 2024, the New England Journal of Medicine published the SURMOUNT-OSA trial results: tirzepatide, the GLP-1/GIP drug sold as Mounjaro and Zepbound, reduced sleep apnea severity by roughly 50% in adults with obesity. The 52-week, placebo-controlled study showed reductions in the apnea-hypopnea index (AHI) of around 20 to 24 events per hour, mean weight loss of approximately 18 to 20% of body weight, and meaningful improvements in blood pressure, inflammation markers, and sleep-related quality of life.

The mainstream coverage celebrated it as a “side benefit” of the GLP-1 class. Press releases called it a breakthrough for sleep apnea patients. The conversations that followed, in clinic visits and patient forums, all framed the same way: the drug is doing more than it was designed to do.

The conversation worth having is different.

What the Study Actually Found

The 52-week SURMOUNT-OSA trials were rigorous: phase 3, double-blind, placebo-controlled, and large enough to draw real conclusions. Two parallel studies enrolled adults with moderate-to-severe obstructive sleep apnea and obesity, with and without PAP (positive airway pressure) therapy use. The headline numbers, as summarized in the NEJM publication and the accompanying editorial:

• AHI reduction: approximately 20 to 24 events per hour vs. placebo, a relative reduction of roughly 48% to 56%
• Weight loss: approximately 18 to 20% of body weight on the higher dose
• Disease resolution criteria met by a substantial fraction of patients in both studies
• Improvements in cardiometabolic markers: systolic blood pressure, hsCRP (a key inflammation marker), and sleep-related patient-reported outcomes

The data is real. The researchers deserve credit for a well-executed trial. The clinical signal is clear: tirzepatide does improve sleep apnea outcomes in this population.

The Framing That Needs a Second Look

The “side benefit” framing only makes sense if the GLP-1 drug is the primary intervention and sleep apnea is an unexpected bonus. But the AHI reduction tracks tightly with the weight loss. The blood pressure improvement tracks with the weight loss. The inflammation improvement tracks with the weight loss. What the trial actually showed is that when you reduce excess weight and improve metabolic function substantially, all of the downstream conditions tied to metabolic dysfunction get better.

Sleep apnea in this population is not an independent disease. It is a downstream consequence of the same underlying metabolic dysfunction that drives the Type 2 diabetes, the cardiovascular risk, and the inflammation. The drug worked on the sleep apnea by working on the upstream cause. The clinical win came from addressing the root.

That is exactly the principle that makes structured reversal protocols work in the first place.

What the Research Says About Reversal

A growing body of peer-reviewed evidence demonstrates that Type 2 diabetes can be put into remission — and in many cases full reversal — through structured nutritional intervention, supplementation, and sustained lifestyle change. The landmark work came from Newcastle University (the original Counterpoint study and follow-ups) and has been replicated in multiple independent settings. The mechanism isn’t a drug. It works at the cellular level by addressing the metabolic dysfunction, insulin resistance, and dietary drivers that caused the disease in the first place.

The SURMOUNT-OSA data, in a sense, validates the underlying principle. When you address the root cause of metabolic dysfunction, the downstream conditions improve. The question is not whether that improvement is possible — the SURMOUNT-OSA data is the latest confirmation that it is. The question is what path to take to get there.

For some patients, the GLP-1 path is the right call. Short-to-medium-term management of a high-risk clinical situation. The new SURMOUNT-OSA data does not change that.

For patients whose goal is sustained reversal — A1c below 6.4% off all medications, and a metabolic profile that supports long-term health without daily prescriptions — the GLP-1 path is a long-term lease, not a long-term fix. The drug works while you take it. The sleep apnea data confirms that the drug works on the root cause while you take it. When you stop taking it, the weight returns, the AHI returns, the inflammation returns, and the disease drivers reassert themselves.

The Bottom Line

The SURMOUNT-OSA trial is a useful, well-designed piece of clinical research. It tells us that effective metabolic intervention improves sleep apnea outcomes. It tells us that the GLP-1 class of drugs produces substantial weight loss and metabolic change in many patients. The physicians who prescribe these drugs are doing what the evidence supports. The patients who take them are making a reasonable choice with the information they have.

What the trial also tells us — quietly, in the data, in the way the AHI tracks the weight loss — is that the underlying metabolic dysfunction is the real target. Address that, and the sleep apnea gets better. Address that, and the A1c gets better. Address that, and the cardiovascular risk gets better. Address that, and the inflammation gets better.

The drug is one path to that improvement. Reversal is another. Both deserve to be on the table. The point isn’t to dismiss one in favor of the other. It’s to make sure patients know both exist, and to let them choose.

For a deeper look at the SURMOUNT-OSA trial design and the AHI outcomes, the peer-reviewed publication is in the New England Journal of Medicine. For patients who want to understand the underlying mechanism of metabolic reversal, the NHS guidance on Type 2 diabetes remission is one of the clearest public-facing summaries available. And the CDC’s National Diabetes Statistics Report makes clear that outcomes across the U.S. population haven’t meaningfully improved in over a decade — which is why the conversation about a different path is worth having.

—

By:

Dr. Jeffrey Hockings
Co-Founder/CEO
Diabetes Reversal Group

Kristine Burke, MD
Chief Medical Officer
Diabetes Reversal Group